Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Device Tax Repeal Tops AdvaMed Priority List For Fiscal-Cliff Bill

This article was originally published in The Gray Sheet

Executive Summary

The post-election, “lame-duck” Congress will face the prospect of letting massive federal spending cuts take effect and multiple tax increases kick in if it does not take action. Device firms hope to leverage the situation to repeal the looming medical device excise tax and make FDA user-fee fixes while avoiding more Medicare provider cuts.

You may also be interested in...



Budget Accord Should Increase FDA Funding, Free Up User Fees

The deal, which sets total FY 2014 discretionary spending at $1.012 trillion, leaves specific appropriations up to congressional committees and frees up user fees from sequestration for two years, both positive developments for FDA’s financial health. Device groups also tout a non-binding provision to repeal the device tax.

Not-So-Happy New Year: Device Tax Not Addressed In Fiscal Cliff Law

There’s no mention of a device tax delay or repeal in the measure signed by President Obama Jan. 2, and the new law contains some Medicare payment cuts as one-year “Doc Fix” pay-fors.

Not-So-Happy New Year: Device Tax Not Addressed In Fiscal Cliff Law

There’s no mention of a device tax delay or repeal in the measure signed by President Obama Jan. 2, and the new law contains some Medicare payment cuts as one-year “Doc Fix” pay-fors.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT031614

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel